Developing OTC products with patented metered-dose platforms for transdermal and intranasal drug delivery
Novvae Pharmaceuticals Inc. is being positioned to meet unmet needs in the antiviral market.
The global topical and intranasal drug delivery markets are on the rise and our products are ready to meet them. With the increase in demand for self-administered and home care, consumers are seeking reliable over-the-counter drugs to manage healthier lifestyles.
Optimizing Intranasal Drug Delivery
in the prophylactic prevention of influenza, covid, and many negatively charged viruses, including the rhino virus (common cold).
AnQlar is a chitosan derivative and a natural antimicrobial delivered as a meter-dosed intranasal nanoparticle dispersion. Its positively charged mucoadhesive attributes create a 24-hour prophylactic barrier against Covid, flu, and the common cold. Its antiviral barrier activity against Covid has been demonstrated in three preclinical studies.
Targeted delivery and viral barrier activity in the nasal mucosa where viruses start
May be used as a frontline defense against disease spread in close settings
May be a viral barrier against influenza and Covid for 24 hours
An adjuvant to barrier-based personal protective equipment (PPE) to help mitigate the risks of poorly fitting equipment and over-used PPE with partially compromised barrier layers
May be used by vaccinated and unvaccinated individuals to prevent viral spread
Demonstrated no viral brain load when exposed to SARS-CoV-2 in preclinical studies
Positioning our pipeline to meet unmet needs in
Multi-billion dollar consumer markets
Global OTC Topical Drugs Market
The global topical drug delivery market is projected to reach $317.8 billion in revenue by 2027, growing at a CAGR of 8.9% from 2022 to 2027.2
Reasons for growth
Increase in demand for self-administered treatments
Increase in aging population
Positioned to Transform the Multibillion-Dollar Non-Prescription
Topical and Transdermal Drug Delivery Market with…
Growth Opportunity (Transdermal)
Our Metered Dose Spray System (MDSS) may be used to deliver OTC products like the oxybutynin transdermal patch for overactive bladder, and the nicotine patch to help stop smoking.
Benefits of MDSS Oxybutynin and Nicotine compared to their current patch formulations
No concern with transdermal adhesion
Satisfactory skin permeation
Reliable and reproducible blood levels
Avoids skin irritation associated with their occlusive backing.
More aesthetically pleasing.
Improved patient compliance could result in better therapeutic outcomes.